Tempest Therapeutics, Inc. TPST

TPST Company Overview

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted and immune-mediated therapeutics for cancer treatment. The company operates within the oncology and biopharmaceutical industries, with research centered on small molecules and biologics designed to modulate tumor pathways and the immune system. Tempest’s primary value proposition is its strategy of combining targeted oncology approaches with immunology-based mechanisms to address difficult-to-treat cancers, particularly solid tumors with limited therapeutic options.

The company’s core pipeline has included programs targeting pathways associated with tumor growth, angiogenesis, and immune suppression. Its lead development candidates have included amezalpat (TPST-1120), a selective PPARα antagonist being evaluated in hepatocellular carcinoma and other oncology indications, and TPST-1495, a dual EP2/EP4 prostaglandin receptor antagonist intended to enhance anti-tumor immune responses. Tempest Therapeutics was formed through the merger of private biotechnology assets and later became publicly traded on the Nasdaq under the ticker TPST following a reverse merger transaction involving Millendo Therapeutics in 2021.